Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer

Cancer Science

Volumn 108, Issue 5, 2017, Pages 1000-1006

  Hida, Toyoaki ^a   Nishio, Makoto ^b   Nogami, Naoyuki ^c   Ohe, Yuichiro ^d   Nokihara, Hiroshi ^d   Sakai, Hiroshi ^e   Satouchi, Miyako ^f   Nakagawa, Kazuhiko ^g   Takenoyama, Mitsuhiro ^h   Isobe, Hiroshi ⁱ   Fujita, Shiro ^j   Tanaka, Hiroshi ^k   Minato, Koichi ^l   Takahashi, Toshiaki ^m   Maemondo, Makoto ⁿ   Takeda, Koji ^o   Saka, Hideo ^p   Goto, Koichi ^q   Atagi, Shinji ^r   Hirashima, Tomonori ^s   Sumiyoshi, Naoki ^t   Tamura, Tomohide ^u   more..

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e SAITAMA CANCER CENTER   (Japan)

^f HYOGO CANCER CENTER   (Japan)

^g KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NATIONAL KYUSHU CANCER CENTER   (Japan)

ⁱ KKR Sapporo Medical Center   (Japan)

^j INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^k NIIGATA CANCER CENTER HOSPITAL   (Japan)

^l GUNMA PREFECTURAL CANCER CENTER   (Japan)

^m SHIZUOKA CANCER CENTER   (Japan)

ⁿ Miyagi Cancer Center   (Japan)

^o OSAKA CITY GENERAL HOSPITAL   (Japan)

^p NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^q NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^r NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^s OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^t ONO PHARMACEUTICAL CO   (Japan)

^u ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

more..

Author keywords

Japanese; Nivolumab; non small cell lung cancer; programmed cell death 1; squamous cell carcinoma

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; DOCETAXEL; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADRENAL CORTEX INSUFFICIENCY; ADVERSE OUTCOME; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ATRIAL FIBRILLATION; AUTOIMMUNE THYROIDITIS; CLINICAL ARTICLE; DECREASED APPETITE; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ENDOCRINE DISEASE; ERYTHEMA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HYPERSENSITIVITY; HYPOALBUMINEMIA; INTERSTITIAL LUNG DISEASE; JAPANESE (PEOPLE); LIVER TOXICITY; LUNG HEMORRHAGE; LUNG TOXICITY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RESPIRATORY FAILURE; SENSORY NEUROPATHY; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STEROID THERAPY; TREATMENT DURATION; TUMOR VOLUME; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL;

EID: 85018271035     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.13225     Document Type: Article

References (21)

1. Bray F, Jemal A, Torre LA, Forman D, Vineis P. Long-term realism and cost-effectiveness: primary prevention in combatting cancer and associated inequalities worldwide. J Natl Cancer Inst 2015; 107: djv273.
2. Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw 2013; 11: 645–53; quiz 53.
3. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359: 1367–80.
4. Zielinski C, Knapp S, Mascaux C, Hirsch F. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol 2013; 24: 1170–9.
5. Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl 3): iii27–39.
6. Hayakawa K. Revised by the Japan Lung Cancer Society: guideline for diagnosis and treatment of lung cancer. Gan To Kagaku Ryoho 2011; 38: 1273–6.
7. Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14: 253–63.
8. Di Maio M, Chiodini P, Georgoulias V et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 1836–43.
9. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–64.
10. Scarpace SL. Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. Drugs Context 2015; 4: 212289.
11. Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8 + T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010; 7: 389–95.
12. Bristol-Myers Squibb. Nivolumab: Prescribing Information, 2015. [Cited on 13 April 2017.] Available from URL: http://packageinserts.bms.com/pi/pi_opdivo.pdf.
13. Bristol-Myers Squibb. Nivolumab: Summary of product characteristics, 2015. [Cited on 13 April 2017.] Available from URL: http://ec.europa.eu/health/documents/community-register/2015/20150720132394/anx_132394_en.pdf.
14. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123–35.
15. Gettinger SN, Horn L, Gandhi L et al. Overall Survival and long-term safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015; 33: 2004–12.
16. Rounds A, Kolesar J. Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer. Am J Health Syst Pharm 2015; 72: 1851–5.
17. Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek E Jr. The 7th lung cancer TNM classification and staging system: review of the changes and implications. World J Radiol 2012; 4: 128–34.
18. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589–97.
19. Kato T, Masuda N, Nakanishi Y et al. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer. Lung Cancer 2017; 104: 111–8.
20. Rizvi NA, Mazières J, Planchard D et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16: 257–65.
21. Passiglia F, Bronte G, Bazan V et al. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget 2016; 7: 19738–47.